Floxuridine History

Floxuridine is a fluorinated pyrimidine monophosphate alternation of 5-fluoro-2'-deoxyuridine-5'-phosphate (FUDR-MP) with antineoplastic activity. As an antimetabolite, floxuridine inhibits thymidylate synthase, consistent in disruption of DNA amalgam and cytotoxicity. This abettor is aswell metabolized to fluorouracil and added metabolites that can be congenital into RNA and arrest the appliance of preformed uracil in RNA synthesis.

Floxuridine aboriginal acquired FDA approval in December 1970 beneath the cast name FUDR. The biologic was initially marketed by Roche, which aswell did a lot of the antecedent plan on 5-fluorouracil. The National Cancer Institute was an aboriginal developer of the drug. Roche awash its FUDR artefact band in 2001 to F H Faulding, which became Mayne Pharma.